Akebia Therapeutics (AKBA) Cash & Equivalents (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Cash & Equivalents data on file, last reported at $162.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $162.6 million, up 43.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $162.6 million (up 43.39% YoY), and the FY2025 annual result was $184.8 million, up 256.36% from the prior year.
• Cash & Equivalents slipped to $162.6 million in Q1 2026 per AKBA's latest filing, from $184.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $184.8 million in Q4 2025 and troughed at $34.0 million in Q3 2024.
• A 5-year average of $99.2 million and a median of $90.5 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 67.87% in 2023, then jumped 389.14% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $90.5 million in 2022, then plunged by 52.55% to $42.9 million in 2023, then gained by 20.84% to $51.9 million in 2024, then jumped by 256.36% to $184.8 million in 2025, then fell by 12.03% to $162.6 million in 2026.
• Business Quant data shows AKBA's Cash & Equivalents at $162.6 million in Q1 2026, $184.8 million in Q4 2025, and $166.4 million in Q3 2025.